Pharming Group (NASDAQ:PHAR) Shares Gap Down – Here’s Why

Pharming Group (NASDAQ:PHAR) shares gapped down before the market opened on Wednesday . The stock had previously closed at $9.25, but opened at $8.95. Pharming Group shares last traded at $8.95, with a volume of 1,342 shares.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group assumed coverage on Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

Pharming Group Trading Down 3.7 %

The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $606.29 million, a P/E ratio of -32.84 and a beta of -0.10. The business has a 50 day moving average of $9.29 and a 200-day moving average of $8.56.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.